Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
Net Income (Common)
Glenmark Life Sciences Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
Net Income (Common)
₹4.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹52.3B
|
CAGR 3-Years
34%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹37.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹89.1B
|
CAGR 3-Years
55%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Net Income (Common)
₹29.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Income (Common)
₹12.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Glenmark Life Sciences Ltd's Net Income (Common)?
Net Income (Common)
4.7B
INR
Based on the financial report for Mar 31, 2023, Glenmark Life Sciences Ltd's Net Income (Common) amounts to 4.7B INR.
What is Glenmark Life Sciences Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
14%
Over the last year, the Net Income (Common) growth was 12%. The average annual Net Income (Common) growth rates for Glenmark Life Sciences Ltd have been 14% over the past three years .